Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R, Soler J: Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected
Ongoing or severe symptoms need medical evaluation to rule out complications and to adjust treatment
Study outcomes According to the treatment-regimen estimand, adults receiving orforglipron 12 mg had a 1.71 percentage point decline in HbA1c, and those receiving orforglipron 36 mg had a 1.91 percentage point drop in HbA1c at 1 year compared with a 1.23 percentage point reduction with semaglutide 7 mg and a 1.47 percentage point decrease with semaglutide 14 mg
In addition, since insurance is more likely to cover semaglutide or tirzepatide for Type 2 Diabetes, it makes sense that states with higher rates will rank higher in usage